Integra Lifesciences Holdings (IART) Income from Continuing Operations (2009 - 2026)

Integra Lifesciences Holdings (IART) has 18 years of Income from Continuing Operations data on file, last reported at 4617000.0 in Q1 2026.

• For the quarter ending Q1 2026, Income from Continuing Operations rose 81.75% year-over-year to 4617000.0; the trailing twelve-month figure through Mar 2026 stood at 495798000.0 (down 1612.31% YoY), and the FY2025 full-year result was 516474000.0, down 7337.7% from the prior year.
• Income from Continuing Operations eased to 4617000.0 in Q1 2026, from 1704000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 52946000.0 in Q4 2022 to a low of 484073000.0 in Q2 2025.
• A 5-year average of 16455470.59 and a median of 4184000.0 in 2023 frame the typical range for Income from Continuing Operations.
• Across the five-year window, Income from Continuing Operations plunged 3803.18% in 2025 and jumped 81.75% in 2026, its largest moves.
• Tracing IART's Income from Continuing Operations over 5 years: stood at 52946000.0 in 2022, then sank by 62.54% to 19834000.0 in 2023, then retreated by 2.01% to 19435000.0 in 2024, then slumped by 108.77% to 1704000.0 in 2025, then slumped by 170.95% to 4617000.0 in 2026.
• Business Quant data shows IART's Income from Continuing Operations at 4617000.0 in Q1 2026, 1704000.0 in Q4 2025, and 5404000.0 in Q3 2025.